TABLE 4.
HR per doubling a (95% CI) | Tertiles per biomarker b | |||
---|---|---|---|---|
Tertile 1 (low) | Tertile 2 (mid) | Tertile 3 (high) | ||
A. Stricturing disease | ||||
C1M | 1.17 (0.79–1.73), p = 0.424 | 0.77 (0.30–1.99), p = 0.768 | 0.51 (0.18–1.44), p = 0.511 | 1.00 (reference) |
C3M | 0.76 (0.29–1.95), p = 0.563 | 1.06 (0.40–2.85), p = 0.906 | 0.96 (0.34–2.75), p = 0.944 | 1.00 (reference) |
PRO‐C3 | 0.66 (0.30–1.45), p = 0.301 | 1.43 (0.53–3.85), p = 0.478 | 0.90 (0.31–2.56), p = 0.836 | 1.00 (reference) |
C3M/PRO‐C3 | 1.16 (0.59–2.30), p = 0.669 | 0.77 (0.30–2.00), p = 0.769 | 0.54 (0.19–1.53), p = 0.542 | 1.00 (reference) |
C4M | 0.85 (0.36–1.97), p = 0.699 | 1.32 (0.51–3.42), p = 0.562 | 0.63 (0.20–1.99), p = 0.630 | 1.00 (reference) |
PRO‐C4 | 1.11 (0.56–2.18), p = 0.764 | 0.53 (0.20–1.38), p = 0.193 | 0.54 (0.20–1.49), p = 0.236 | 1.00 (reference) |
PRO‐C4/C4M | 1.78 (0.53–5.99), p = 0.352 | 0.37 (0.13–1.06), p = 0.063 | 0.54 (0.21–1.40), p = 0.207 | 1.00 (reference) |
C4G | 1.08 (0.61–1.89), p = 0.800 | 0.86 (0.36–2.07), p = 0.739 | 0.26 (0.07–1.03), p = 0.065 | 1.00 (reference) |
C6Ma3 | 2.01 (0.89–4.57), p = 0.095 | 0.61 (0.21–1.76), p = 0.360 | 1.19 (0.46–3.09), p = 0.720 | 1.00 (reference) |
B. Penetrating disease | ||||
C1M | 1.33 (0.90–1.97), p = 0.154 | 1.00 (reference) | 5.91 (1.31–26.7), p = 0.021 | 4.73 (1.00–22.3), p = 0.049 |
C3M | 2.18 (0.87–5.47), p = 0.098 | 1.00 (reference) | 0.51 (0.15–1.68), p = 0.265 | 1.48 (0.58–3.77), p = 0.411 |
PRO‐C3 | 1.16 (0.50–2.69), p = 0.723 | 1.00 (reference) | 0.75 (0.25–2.25), p = 0.609 | 1.21 (0.45–3.26), p = 0.707 |
C3M/PRO‐C3 | 1.33 (0.69–2.53), p = 0.393 | 1.00 (reference) | 1.17 (0.39–3.49), p = 0.777 | 1.74 (0.62–4.93), p = 0.296 |
C4M | 1.53 (0.69–3.39), p = 0.297 | 1.00 (reference) | 1.52 (0.53–4.38), p = 0.440 | 1.64 (0.57–4.74), p = 0.365 |
PRO‐C4 | 2.24 (1.07–4.71), p = 0.033 | 1.00 (reference) | 1.91 (0.62–5.89), p = 0.258 | 2.10 (0.70–6.28), p = 0.184 |
PRO‐C4/C4M | 4.81 (1.13–20.4), p = 0.033 | 1.00 (reference) | 1.58 (0.52–4.85), p = 0.420 | 1.86 (0.62–5.55), p = 0.266 |
C4G | 1.71 (1.05–2.81), p = 0.032 | 1.00 (reference) | 0.53 (0.13–2.11), p = 0.366 | 2.66 (1.01–7.01), p = 0.048 |
C6Ma3 | 2.00 (0.87–4.62), p = 0.104 | 1.00 (reference) | 3.03 (0.95–9.67), p = 0.062 | 2.30 (0.69–7.64), p = 0.175 |
C. Surgical interventionsc | ||||
C1M | 1.39 (0.94–2.06), p = 0.099 | 1.00 (reference) | 2.14 (0.66–6.98), p = 0.208 | 3.13 (0.96–10.2), p = 0.059 |
C3M | 1.24 (0.49–3.12), p = 0.648 | 1.00 (reference) | 0.48 (0.15–1.57), p = 0.226 | 1.19 (0.47–3.01), p = 0.714 |
PRO‐C3 | 1.01 (0.42–2.44), p = 0.975 | 1.00 (reference) | 0.50 (0.16–1.53), p = 0.223 | 1.05 (0.40–2.72), p = 0.922 |
C3M/PRO‐C3 | 1.12 (0.56–2.25), p = 0.752 | 1.00 (reference) | 0.70 (0.24–2.01), p = 0.504 | 1.13 (0.42–3.04), p = 0.806 |
C4M | 1.07 (0.47–2.39), p = 0.879 | 1.00 (reference) | 1.01 (0.36–2.78), p = 0.993 | 1.10 (0.40–3.06), p = 0.854 |
PRO‐C4 | 1.41 (0.70–2.87), p = 0.340 | 1.00 (reference) | 1.67 (0.58–4.86), p = 0.345 | 1.75 (0.60–5.08), p = 0.304 |
PRO‐C4/C4M | 2.76 (0.64–11.9), p = 0.173 | 1.00 (reference) | 1.18 (0.40–3.51), p = 0.767 | 1.64 (0.58–4.61), p = 0.352 |
C4G | 1.00 (0.55–1.80), p = 0.990 | 1.00 (reference) | 0.23 (0.05–1.05), p = 0.058 | 1.46 (0.61–3.54), p = 0.398 |
C6Ma3 | 2.08 (0.87–5.00), p = 0.101 | 1.00 (reference) | 2.61 (0.88–7.67), p = 0.082 | 1.80 (0.57–5.71), p = 0.320 |
Abbreviations: CI, confidence interval; HR, hazard ratio; MV, multivariable analysis; UV, univariable analysis.
Biomarker levels were 2log‐transformed before entry into the model as a continuous predictor, facilitating results interpretation (per doubling).
Per biomarker, levels were divided into tertiles with the lowest tertile (Tertile 1) set as a reference standard in the model.